Cutler Group’s Abeona Therapeutics ABEO Stock Holding History

Cutler Group’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-28	Closed	-$1K	–	4011
2018 Q2	$1K	Hold	28	–	–	﹤0.01%	3738
2018 Q1	$1K	Sell	28 -660	-96%	-$245K	﹤0.01%	3947
2017 Q4	$63K	Sell	688 -2,184	-76%	-$903K	﹤0.01%	1690
2017 Q3	$486K	Buy	2,872 +2,664	+1,281%	+$716K	0.02%	674
2017 Q2	$7K	Sell	208 -292	-58%	-$39.8K	﹤0.01%	4479
2017 Q1	$6K	Buy	+500	New	+$64.5K	﹤0.01%	4495

Other funds holding ABEO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Cutler Group's ABEO Position: Q1 2020 in Review

Cutler Group sold out of Abeona Therapeutics (ABEO) in Q1 2020, closing a stake of 40 shares — an estimated $3K sold.

Cutler Group first reported a position in ABEO in Q4 2015 and held it in 12 quarters. The position peaked at $289K in Q3 2017. 80 funds tracked by Wall St. Rank hold ABEO as of Q1 2020.

Cutler Group reported no remaining Abeona Therapeutics position as of Q1 2020 after selling out during the quarter.
Cutler Group sold 40 Abeona Therapeutics shares in Q1 2020, an estimated $3K.
Cutler Group first reported a position in Abeona Therapeutics in Q4 2015 and held it in 12 quarters.
Cutler Group's Abeona Therapeutics position peaked at $289K in Q3 2017.
80 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2020.

Based on Cutler Group's 13F filing for Q1 2020, filed 7 May 2020.